Related Experiment Video

Updated: Jun 9, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

The challenges and clinical landscape of glioblastoma immunotherapy

Andrew Timothy Ng1, Tyler Steve1, Kevin T Jamouss1

  • 1Department of Medicine, University of Massachusetts Chan Medical School - Baystate Campus, Springfield, MA 01199, USA.

CNS Oncology
|October 29, 2024
PubMed

Insights

Glioblastoma immunotherapy trials show limited success, with only one vaccine demonstrating a statistically significant survival benefit. Further research is needed to establish immunotherapy

Area of Science:

  • Neuro-oncology
  • Immunology
  • Clinical Trials

Background:

  • Glioblastoma (GBM) has a poor prognosis despite standard treatments like surgery, radiation, and temozolomide.
  • Identifying effective treatments for GBM remains a significant challenge in neuro-oncology.

Purpose of the Study:

  • To review the challenges in treating glioblastoma.
  • To analyze the outcomes of glioblastoma immunotherapy clinical trials, focusing on Phase III studies.

Main Methods:

  • Systematic review of published Phase III glioblastoma immunotherapy trials.
  • Analysis of survival-related outcomes, including median survival data.

Main Results:

  • Over 100 glioblastoma immunotherapy trials have been conducted.
  • The DCVax-L vaccine trial showed a statistically significant increase in median survival (19.3 vs. 16.5 months) but used an external control group, limiting evidence quality.

Conclusions:

  • Current glioblastoma immunotherapy research has yielded limited success in improving patient survival.
  • Further investigation is required to determine the role and efficacy of immunotherapy in glioblastoma treatment.
Keywords:
cancer vaccinesclinical researchclinical trialsdrug resistanceglioblastomaimmunotherapy

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.8K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
342